Tipo
Artigos em Revista
Tipo de Documento
Artigo Completo
Título
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR
Participantes na publicação
Miquéias Lopes-Pacheco (Author)
BioISI - Biosystems & Integrative Sciences Institute
Dep. Química e Bioquímica
BioISI
Iris A.L. Silva (Author)
Mark J. Turner (Author)
Graeme W. Carlile (Author)
Elvira Sondo (Author)
David Y. Thomas (Author)
Nicoletta Pedemonte (Author)
John W. Hanrahan (Author)
Margarida D. Amaral (Author)
Dep. Química e Bioquímica
BioISI
Resumo
Despite progress in developing pharmacotherapies to rescue F508del-CFTR, the most prevalent Cystic Fibrosis (CF)-causing mutation, individuals homozygous for this mutation still face several disease-related symptoms. Thus, more potent compound combinations are still needed. Here, we investigated the mechanism of action (MoA) of RDR01752, a novel F508del-CFTR trafficking corrector. F508del-CFTR correction by RDR01752 was assessed by biochemical, immunofluorescence microscopy and functional assays in cell lines and in intestinal organoids. To determine the MoA of RDR01752, we assessed its additive effects to those of genetic revertants of F508del-CFTR, the FDA-approved corrector drugs VX-809 and VX-661, and low temperature. Our data demonstrated that RDR01752 rescues F508del-CFTR processing and plasma membrane (PM) expression to similar levels of VX-809 in cell lines, although RDR01752 produced lower functional rescue. However, in functional assays using intestinal organoids (F508del/F508del), RDR01752, VX-809 and VX-661 had similar efficacy. RDR01752 demonstrated additivity to revertants 4RK and G550E, but not to R1070W, as previously shown for VX-809. RDR01752 was also additive to low temperature. Co-treatment of RDR01752 and VX-809 did not increase F508del-CFTR PM expression and function compared to each corrector alone. The lack of additivity of RDR01752 with the genetic revertant R1070W suggests that this compound has the same effect as the insertion of tryptophan at 1070, i.e., filling the pocket at the NBD1:ICL4 interface in F508del-CFTR, similarly to VX-809. Combination of RDR01752 with correctors mimicking the rescue by revertants G550E or 4RK could thus maximize rescue of F508del-CFTR.
Data de Submissão/Pedido
2020-04-22
Data de Aceitação
2020-06-30
Data de Publicação
2020-10
Suporte
Biochemical Pharmacology
Identificadores da Publicação
ISSN - 0006-2952
Editora
Elsevier BV
Identificadores do Documento
DOI -
https://doi.org/10.1016/j.bcp.2020.114133
URL -
http://dx.doi.org/10.1016/j.bcp.2020.114133
Identificadores de Qualidade
Web Of Science Q1 (2019) - 4.960 - PHARMACOLOGY & PHARMACY - SCIE
SCOPUS Q1 (2019) - 7.5 - Biochemistry
SCOPUS Q1 (2019) - 7.5 - Pharmacology
SCIMAGO Q1 (2019) - 1.509 - Pharmacology
Web Of Science Q1 (2020) - 5.858 - PHARMACOLOGY & PHARMACY - SCIE
SCIMAGO Q1 (2020) - 1.595 - Biochemistry
SCIMAGO Q1 (2020) - 1.595 - Pharmacology
SCOPUS Q1 (2020) - 8.4 - Pharmacology
SCOPUS Q1 (2020) - 8.4 - Biochemistry
SCIMAGO Q1 (2019) - 1.509 - Biochemistry
Download